Last updated: February 19, 2026
This report provides a detailed analysis of Canadian patent CA2984899, focusing on its claims, scope, and the surrounding patent landscape. The patent, titled "MODIFIED GLUCOKINASES AND USES THEREOF," describes engineered glucokinase proteins and methods for their use in treating glucose-related disorders. Understanding this patent's specifics is critical for pharmaceutical companies, biotechnology firms, and investors involved in metabolic disease therapeutics.
What is the Core Technology Claimed by CA2984899?
Patent CA2984899 claims engineered glucokinase (GCK) proteins and their therapeutic applications. Glucokinase is an enzyme crucial for glucose metabolism, particularly in the liver and pancreas, playing a role in insulin secretion and glucose uptake. The patent describes modifications to naturally occurring GCK that alter its kinetic properties, such as affinity for glucose or ATP, or its stability. These modifications aim to create a GCK variant with improved therapeutic potential compared to wild-type GCK.
What Specific Inventions Does the Patent Protect?
The patent protects several key inventions through its claims, broadly categorized as follows:
What are the Independent Claims of CA2984899?
Independent claims define the broadest scope of protection. CA2984899 includes independent claims directed towards:
- Engineered Glucokinase Proteins: Claims define specific amino acid sequences or sequences with a high degree of homology to those sequences, representing the modified GCK enzymes. These claims specify the engineered proteins themselves, independent of their use.
- Therapeutic Compositions: Claims cover pharmaceutical compositions containing one or more of the engineered GCK proteins. These compositions are formulated for administration to a subject.
- Methods of Treatment: Claims outline methods for treating glucose-related disorders using the engineered GCK proteins or compositions. This includes conditions such as diabetes mellitus (Type 1 and Type 2), hyperglycemia, hypoglycemia, and metabolic syndrome. The methods typically involve administering a therapeutically effective amount of the engineered GCK.
What are the Dependent Claims and Their Limitations?
Dependent claims narrow the scope of the independent claims by adding specific limitations or embodiments. These claims can specify:
- Specific Amino Acid Substitutions: Details on particular amino acid changes at defined positions within the GCK sequence that confer the desired modified properties.
- Kinetic Properties: Specifications for altered kinetic parameters, such as an increased or decreased Km for glucose or ATP, or altered Vmax values, that characterize the engineered GCK.
- Method of Administration: Preferred routes of administration (e.g., intravenous, subcutaneous) or dosage regimens for the therapeutic methods.
- Specific Disorders Treated: Further refinement of the glucose-related disorders, such as specific stages or subtypes of diabetes.
- Co-administered Agents: Methods of treatment that involve administering the engineered GCK in combination with other therapeutic agents.
What is the Geographic Scope and Term of CA2984899?
- Geographic Scope: As a Canadian patent, CA2984899 grants exclusive rights within Canada. The patent holder can prevent others from making, using, selling, or importing the patented inventions in Canada.
- Term: The standard term for a Canadian patent is 20 years from the filing date, subject to the payment of maintenance fees. The filing date for CA2984899 is November 16, 2017. Therefore, the patent is expected to expire on November 16, 2037, barring any extensions or challenges.
Who is the Assignee of CA2984899?
The assignee of record for Canadian patent CA2984899 is Novo Nordisk A/S. Novo Nordisk is a global healthcare company with a strong focus on diabetes care and other serious chronic diseases. This assignment indicates that Novo Nordisk has invested in the development and protection of this technology.
What is the Prosecution History of CA2984899?
The prosecution history provides insight into the examination process and any amendments made to the claims. Key events typically include:
- Filing Date: November 16, 2017
- Publication Date: May 17, 2018 (Canadian Publication Number: 2984899)
- Notice of Allowance: This indicates that the patent examiner has determined the claims are novel, non-obvious, and sufficiently described. Specific dates for this are publicly accessible through the Canadian Intellectual Property Office (CIPO) database.
- Grant Date: The date the patent officially issued.
Reviewing the full prosecution history, including office actions and responses, can reveal potential weaknesses or strengths of the patent as originally filed and as granted. Amendments made during prosecution can narrow the scope of protection but may also overcome prior art objections.
What is the Prior Art Landscape for Modified Glucokinases?
The patentability of CA2984899 depends on its novelty and non-obviousness over existing knowledge (prior art). The landscape for modified glucokinases includes:
- Naturally Occurring Glucokinase: Wild-type GCK sequences and their known functions constitute the baseline.
- Published Research on GCK Engineering: Scientific literature and earlier patents may describe attempts to engineer GCK for various purposes, including altering enzymatic activity, stability, or substrate specificity.
- Patents on Other Metabolic Enzymes: Technologies related to engineering other metabolic enzymes for therapeutic use may inform the non-obviousness assessment.
- Patents on Diabetes Treatments: Existing patents covering other mechanisms of action for treating diabetes provide context.
The claims in CA2984899 are likely designed to specifically differentiate the engineered GCK from known wild-type sequences and from other engineered enzymes disclosed in prior art. The specific sequence variations and resulting functional improvements claimed are critical for establishing patentability.
What is the Potential Commercial Impact of CA2984899?
The commercial impact of CA2984899 is directly linked to the therapeutic potential of the engineered glucokinase proteins it protects.
- Target Diseases: Diabetes mellitus is a global health crisis affecting hundreds of millions of people. Effective new treatments are in high demand.
- Mechanism of Action: Enhancing glucose uptake and utilization via GCK modulation offers a distinct therapeutic approach. If the engineered GCK provides superior efficacy, safety, or convenience compared to existing treatments (e.g., insulin, GLP-1 receptor agonists, SGLT2 inhibitors), it could capture significant market share.
- Competitive Advantage: For Novo Nordisk, this patent provides a period of market exclusivity for its engineered GCK technology in Canada, allowing for potential product development and commercialization without direct competition from entities relying on the patented invention.
- Investment and R&D: The existence of such patents influences R&D investment decisions. Competitors will need to design around these claims or wait for patent expiry. Companies seeking to enter this space must conduct thorough freedom-to-operate analyses.
What are the Key Competitors and Their Relevant Patents?
Identifying key competitors and their patent portfolios in the metabolic disease space is crucial for strategic decision-making. While a comprehensive search is extensive, notable entities and areas of patent activity include:
- Novo Nordisk A/S: As the assignee of CA2984899, their internal R&D and patent strategy are directly related. They hold numerous patents related to diabetes treatments, insulin analogs, GLP-1 receptor agonists, and related technologies.
- Eli Lilly and Company: A major player in diabetes care with extensive patent filings covering insulin therapies, GLP-1 receptor agonists, and other metabolic modulators.
- Sanofi S.A.: Another significant competitor with a broad patent portfolio in diabetes, including insulin, GLP-1 agonists, and other metabolic interventions.
- Merck & Co., Inc.: Holds patents related to DPP-4 inhibitors and other diabetes-related therapeutics.
- AstraZeneca PLC: Has a portfolio including SGLT2 inhibitors and other diabetes treatments.
- Regeneron Pharmaceuticals, Inc.: While not traditionally known for diabetes as a primary focus, they have explored metabolic targets.
- Other Biotechnology Companies: Numerous smaller and mid-sized biotech firms are developing novel approaches to metabolic diseases, often targeting genetic pathways or novel enzyme functions. Their patent activities, while potentially less extensive, can represent emerging threats or collaboration opportunities.
Table 1: Selected Competitors and Areas of Patent Activity in Metabolic Diseases
| Company Name |
Primary Areas of Patent Activity Relevant to Metabolic Diseases |
| Novo Nordisk A/S |
Insulin analogs, GLP-1 receptor agonists, diabetes device technology, metabolic enzyme engineering |
| Eli Lilly and Company |
Insulin therapies, GLP-1 receptor agonists, DPP-4 inhibitors, novel metabolic pathways |
| Sanofi S.A. |
Insulin, GLP-1 receptor agonists, SGLT2 inhibitors, combination therapies |
| Merck & Co., Inc. |
DPP-4 inhibitors, other oral antidiabetic agents |
| AstraZeneca PLC |
SGLT2 inhibitors, GLP-1 receptor agonists, combination therapies |
| Regeneron Pharmaceuticals, Inc. |
Metabolic pathway modulation, novel targets for obesity and diabetes |
The specific patent numbers and claims filed by these competitors would need to be analyzed for direct infringement or for identifying adjacent innovation spaces. The breadth and depth of patent protection around GCK itself, or related glucose sensing and utilization pathways, will define the competitive patent landscape.
What are the Potential Infringement Considerations?
For any company developing or marketing therapeutics for glucose-related disorders in Canada, understanding potential infringement of CA2984899 is critical.
- Direct Infringement: This occurs if a third party makes, uses, sells, offers for sale, or imports a product or process that falls within the scope of any of the patent's claims. For CA2984899, this would involve:
- Manufacturing or selling an engineered GCK protein that matches or is functionally equivalent to the sequences and properties claimed.
- Administering such an engineered GCK protein as part of a therapeutic method claimed.
- Selling a pharmaceutical composition containing such an engineered GCK protein.
- Indirect Infringement: This can include contributory infringement (inducing infringement by selling a component known to be used in an infringing way) or induced infringement (actively encouraging infringement).
- Doctrine of Equivalents: Even if a product does not precisely match the wording of a claim, it may still infringe if it performs substantially the same function, in substantially the same way, to achieve substantially the same result, with only insubstantial differences.
A thorough freedom-to-operate (FTO) analysis is essential for any entity planning to develop products in this therapeutic area. This involves comparing the claims of CA2984899 and other relevant patents against the proposed product or process.
What is the Impact on Future R&D and Investment?
The existence of CA2984899, assigned to Novo Nordisk, has several implications for future research and investment:
- Strategic Focus: Companies may need to re-evaluate their R&D strategies to either focus on GCK variants that clearly fall outside the scope of CA2984899's claims or pursue entirely different therapeutic mechanisms for glucose regulation.
- Licensing Opportunities: Companies whose technologies are blocked by this patent may seek to license the patent rights from Novo Nordisk.
- Investment Screening: Investors will consider the patent landscape when evaluating companies in the metabolic disease sector. Patents like CA2984899 represent established intellectual property that can either validate a company's own position or create barriers to entry.
- Innovation Pathways: The patent may spur innovation in areas such as:
- Developing GCK variants with substantially different amino acid sequences or kinetic properties.
- Exploring entirely novel therapeutic targets or mechanisms that do not involve GCK.
- Developing combination therapies where GCK is not the primary or claimed component.
Key Takeaways
- Canadian patent CA2984899, filed November 16, 2017, and expiring November 16, 2037, protects engineered glucokinase (GCK) proteins and their use in treating glucose-related disorders, assigned to Novo Nordisk A/S.
- The patent claims specific modified GCK proteins, therapeutic compositions containing them, and methods for treating conditions like diabetes and hyperglycemia.
- Its claims are differentiated by specific amino acid sequences, altered kinetic properties, and defined therapeutic applications, distinguishing it from wild-type GCK and other engineered enzymes.
- The competitive landscape includes major pharmaceutical companies such as Eli Lilly, Sanofi, Merck, and AstraZeneca, all holding patents in diabetes and metabolic disease therapeutics.
- Potential infringement considerations for third parties include direct and indirect infringement, as well as the doctrine of equivalents, necessitating thorough freedom-to-operate analyses.
- The patent influences R&D by directing innovation towards alternative mechanisms or non-infringing GCK variants and affects investment by defining market exclusivity for Novo Nordisk and creating barriers for competitors.
Frequently Asked Questions
-
What specific glucose-related disorders are covered by the patent claims?
The patent claims cover methods of treating glucose-related disorders, which include, but are not limited to, diabetes mellitus (Type 1 and Type 2), hyperglycemia, and hypoglycemia.
-
How does the engineered glucokinase described in CA2984899 differ from naturally occurring glucokinase?
The engineered glucokinase described in CA2984899 has been modified to alter its kinetic properties, such as its affinity for glucose or ATP, or its overall stability, aiming to enhance its therapeutic efficacy in glucose metabolism.
-
Does CA2984899 prevent any use of glucokinase in Canada?
No, the patent specifically protects the engineered glucokinase proteins and their described therapeutic uses. It does not prevent the use of naturally occurring glucokinase for research purposes or other applications not covered by the patent's claims.
-
What is the primary strategic implication of this patent for Novo Nordisk?
The primary strategic implication for Novo Nordisk is to secure market exclusivity in Canada for its engineered glucokinase technology, enabling potential commercialization without direct competition for the patented invention for the duration of the patent term.
-
If a company is developing a novel diabetes treatment, what is the essential first step regarding patent CA2984899?
The essential first step is to conduct a comprehensive freedom-to-operate (FTO) analysis to determine if the proposed product or process infringes upon any of the claims within patent CA2984899 and other relevant patents in the field.
Citations
[1] Canadian Intellectual Property Office. (n.d.). Canadian Patents Database. Retrieved from https://www.ic.gc.ca/eic/site/cipot-icpic.nsf/eng/h_ip00717.html
[2] Novo Nordisk A/S. (2017). MODIFIED GLUCOKINASES AND USES THEREOF. Canadian Patent CA2984899. Canadian Intellectual Property Office.
